

Safety and efficacy study of lung cancer stem cell vaccine

Mao Lin, Shu-Ying Li, Ke-Cheng Xu, Zheng-Ping Liu, Feng Mu, Yuan-Ying Yuan, Xiao-Hua Wang, Ji-Bing Chen & Qiao Li

Immunologic Research

ISSN 0257-277X

Immunol Res

DOI 10.1007/s12026-015-8631-7



Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media New York. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

Safety and efficacy study of lung cancer stem cell vaccine

Mao Lin · Shu-Ying Li · Ke-Cheng Xu ·
Zheng-Ping Liu · Feng Mu · Yuan-Ying Yuan ·
Xiao-Hua Wang · Ji-Bing Chen · Qiao Li

© Springer Science+Business Media New York 2015

Abstract In this trial, lung cancer stem cells (CSCs) were separated and cultured to produce a vaccine; its safety and efficacy were prospectively evaluated in low-, medium-, and high-dose groups. Between February and September 2014, we enrolled 90 patients who met the enrollment criteria and assigned them to three groups ($n = 30$). Throughout the trial, injection site reaction was the most common reaction (63 %), and fever was least common (16 %); however, there was no difference among the three groups. When the immune responses pre- and post-vaccination were compared, we found that the CSC-nonspecific and CSC-specific responses were both significantly enhanced in the medium- and high-dose groups. This study is the first clinical trial of a lung CSC vaccine and preliminarily proves its safety and efficacy.

Keywords Cancer stem cell · Vaccine · Lung cancer · Safety · Efficacy

Introduction

Lung cancer-related mortality is almost invariably due to metastasis [1]. More than 50 % of patients diagnosed with lung cancer will eventually develop deadly metastases,

often years after the primary tumor is diagnosed and removed [2]. The therapeutic alternatives for metastatic lung cancer are mainly based on the systemic administration of cytotoxic chemotherapeutic agents [3]; the long-term impact on survival depends greatly on the nature of the metastases and tumor biology [4]. Many pilot studies have confirmed the good therapeutic effects and fewer side effects, such as radiofrequency ablation or cryoablation [5, 6]; dendritic cell-cytokine-induced killer (DC-CIK) immunotherapy may have powerful therapeutic effects under low burden load conditions [7, 8].

Traditional DC-CIK immunotherapy supplements lymphocyte count and function effectively [9, 10], but has no tumor specificity, and it is difficult to form a memory immune response for long-term prevention of tumor recurrence. Currently, accumulating evidence suggests that a tumor cell subpopulation with distinct stem cell-like properties (the so-called cancer stem cells, CSCs) is responsible for the initiation, invasion, and metastasis of lung cancer [11–13]. In the laboratory, CSCs are identified by the CD133 surface marker and their ability to form new lung cancer colonies through serial transplantations in immunodeficient hosts, re-establishing tumor heterogeneity [14, 15].

To assess the feasibility of generating CSC vaccines for clinical use, we harvested peripheral blood and tumor specimens from patients with lung cancer. Lymphocytes were isolated from peripheral blood mononuclear cells (PBMCs); CSCs were isolated from the tumor specimens. CSC-specific and CSC-nonspecific immunity induced by cytotoxic T cells and antibodies, and adverse event occurrence were compared before and after the trial. CSC-specific and CSC-nonspecific immunities were both obviously increased in the medium- and high-dose groups; adverse events that occurred were mild and quickly resolved.

M. Lin · S.-Y. Li · K.-C. Xu · Z.-P. Liu · F. Mu · Y.-Y. Yuan ·
X.-H. Wang · J.-B. Chen (✉)
Fuda Cancer Hospital, Jinan University School of Medicine,
Guangzhou, China
e-mail: jibingchen398@163.com

Q. Li
Comprehensive Cancer Center, University of Michigan, Ann
Arbor, MI, USA
e-mail: qiaoli@umich.edu

Materials and methods

Ethics

This clinical trial was registered in the US National Institutes of Health (ID: NCT02084823; Ph1/Ph2) and approved by the Ethics Committee of Guangzhou Fuda Cancer Hospital. In accordance with the Declaration of Helsinki, written informed consent was obtained from each participant in Fuda Cancer Hospital.

Patient selection

This was a prospective study of the therapeutic effects of a CSC vaccine for lung cancer patients enrolled between February and September 2014. We enrolled 90 patients using the following criteria: (1) had at least one resectable tumor, and other tumors could be well controlled by cryosurgery, radiofrequency ablation, or chemotherapy, (2) expected survival >3 months, (3) aged 30–80 years, (4) Karnofsky performance status >70, (5) the following parameters were normal: total T cells, 603–2990/ μ L; cytotoxic T cells, 125–1312/ μ L; helper T (Th) cells, 441–2156/ μ L; platelets, $\geq 80 \times 10^9$ /L; white blood cells, $\geq 3 \times 10^9$ /L; neutrophils, $\geq 2 \times 10^9$ /L; hemoglobin, ≥ 90 g/L; prothrombin time international normalized ratio, 0.8–1.5; adequate hepatic function (bilirubin <20 μ M, aminotransferase <60 U/L) and renal function (serum creatinine <130 μ M, serum urea <10 mM), (6) absence of level 3 hypertension, severe coronary disease, myelosuppression, respiratory disease, acute or chronic infection, and autoimmune diseases. The contraindications for participation were T cell lymphoma, ongoing organ transplant, or within 7 days after systemic chemotherapy. The enrolled patients were allocated to three groups ($n = 30$) with parallel assignments.

Preparation of CSC vaccine

The CSC vaccine contained three components: lung CSC fragments, multi-oil fat emulsion injection (C_{6–24}; Frese-nius Kabi GmbH, Graz-Puntigam, Austria), and Mannatide injection (Duokang; Chengdu Lier Pharmaceutical, Chengdu, China). The total vaccine volume was 0.5 mL: 0.3 mL CSC/saline solution (10^5 , 3×10^5 , and 5×10^5 CSCs for the low-, medium-, and high-dose groups, respectively) and 0.1 mL each of the remaining components.

The CSC preparation process involved seven steps: (1) solid tumor resection (e.g., primary lesion or metastasis in liver or lung, generally diameter >4 cm), (2) preparation of single-cell suspensions using a human Tumor Dissociation Kit (no. 130-095-929; Miltenyi Biotec, Bergisch Gladbach, Germany), (3) CSC separation using a human CD133

MicroBead Kit (no. 130-050-801; clone AC133; Miltenyi Biotec), (4) CSC amplification and culture using a human StemMACS MSC Expansion Media Kit XF (no. 130-104-182; Miltenyi Biotec), (5) detection of cell purity by phycoerythrin (PE) anti-human CD133 (no. 130-090-853; clone 293C3; Miltenyi Biotec), (6) cell counting and reserving at different concentrations, (7) CSC lysis by repeated freezing and thawing five times. All steps were performed in accordance with the corresponding instructions.

Vaccinations and tests

Based on our previously reported animal experiments [16], the vaccination period involved two subcutaneous injections on both sides of the deltoid muscle, interspersed with a 1-week interval. Before and 1 week after vaccination, ~30 mL peripheral blood was drawn for in vitro testing (Fig. 1).

Peripheral blood (2 mL) was used for detecting CSC-nonspecific immunity by flow cytometry (FACSCanto™ II; BD, Franklin Lakes, NJ, USA). Multitest 6-color TBNK Reagent (no. 644611; BD) was used to detect the number of lymphocyte subsets; Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit II (no. 551809; BD) was used to detect cytokine expression levels. All steps were performed in accordance with the corresponding instructions.

Using Ficoll-Hypaque density centrifugation, PBMCs and plasma were harvested from the remaining blood samples, and CSC-specific immunity induced by cytotoxic T cells and antibodies were compared before and after the trial. CSC-specific testing included CSC binding by immune plasma, and complement-dependent cytotoxicity (CDC) and cytotoxic T lymphocyte (CTL) tests. Plasma CSC-binding antibodies were detected using fluorescein isothiocyanate anti-human immunoglobulin G (IgG, no. 130-099-229; clone IS11-3B2.2.3; Miltenyi Biotec); we have described the protocols previously [16]. T lymphocytes were separated by human CD3 MicroBeads (no. 130-050-101; Miltenyi Biotec), activated by anti-human CD3/28 (no. 300314/302934, BioLegend, San Diego, CA, USA), and expanded using interleukin (IL)-2 (no. 200-02, PeproTech, Rocky Hill, NJ, USA); DCs were induced and cultured in IL-4 (no. 200-04, PeproTech) and granulocyte-macrophage colony-stimulating factor (no. 300-03, PeproTech); we have described the protocols previously [17].

Evaluation and statistical analysis

Complications were recorded and classified in accordance with the Common Terminology Criteria of Adverse Events version 4.02. Radiographic local tumor control was

Fig. 1 Vaccination and test schedule and trend chart of CSC numbers. *Broken lines* represent the gradual amplification of CSCs and single consumption during vaccination or testing




Table 1 Patient demographics

Patient characteristics before vaccination	Total (n = 90)	Low-dose group (n = 30)	Medium-dose group (n = 30)	High-dose group (n = 30)	P value
Gender (male/female)	43/47	16/14	13/17	14/16	>0.05
Median age (years)	52	53	54	47	>0.05
Tumor histology					
Adenocarcinomas	47	17	16	14	>0.05
Squamous cell carcinomas	40	12	14	14	>0.05
Adenosquamous carcinomas	3	1	0	2	>0.05
Clinical stage (AJCC)					
III	47	15	19	13	>0.05
IV	43	15	11	17	
Karnofsky performance status					
80	36	13	9	14	>0.05
90	34	11	14	9	>0.05
100	20	6	7	7	>0.05
Chemotherapy	45	13	17	15	>0.05
Cryosurgery/radiofrequency ablation	48	14	18	16	>0.05
Surgery	90	30	30	30	>0.05

Factors of low-, middle- and high-dose group were compared by two-way ANOVA

AJCC American Joint Committee on Cancer staging system

assessed using image-guided tumor ablation criteria [18]. Patient demographics were compared among the three groups before vaccination by two-way analysis of variance (ANOVA); CSC-specific and CSC-nonspecific immunity pre- and post-vaccination were compared by Dunnett's multiple comparison test (one-way ANOVA), and detection result data are presented as the mean \pm standard deviation; local and systemic adverse events were marked in the nursing records and compared using the Chi-square test. All analyses were conducted using GraphPad software (GraphPad, San Diego, CA, USA).

Results

Identification of CSCs in enrolled patients

According to the protocol depicted in Fig. 1, all enrolled patients underwent surgical resection before the CSCs were separated in the laboratory. Before separation, CSC purity was $2.4 \pm 0.5\%$; after separation, CSC purity increased up to $92 \pm 9\%$ (Fig. 2). All CSCs separated from the tumor mass were sufficient for culture, vaccination, and testing, and CD133+ cell purity after 2- and 4-week

Fig. 2 CSCs in lung cancer mass. **a** CSC purity in tumor cell suspension before separation. **b** CSC purity in separation products obtained using the human CD133 MicroBead Kit





Fig. 3 Local and systemic adverse events. The incidences of each Grade 1 adverse event that occurred in the three groups are depicted in separate columns; figures above the columns indicate the average incidences in all patients

culture was similar to that immediately following separation (figures not shown).

Clinical data

All pre-treatment information was collected from 90 patients of our hospital, which were from China (23), Indonesia (25), Malaysia (19) and Mid East (23), respectively. The data of the three groups were compared, and there was no statistical difference for the patient demographics (Table 1).

Adverse events

Throughout the trial, all adverse events experienced by the patients were recorded and included local (mainly injection site reaction or localized edema) and systemic (mainly chills, fatigue, or fever) reactions. Other possible side effects such as blood or bone marrow changes were not detected. All

adverse events were Grade 1; after symptomatic treatment, all symptoms were relieved within the day and did not reappear. Adverse event occurrence was compared using the Chi-square test; there was no difference among the three groups ($P = 0.9921$, Fig. 3). Among the patients, the most common reaction was injection site reaction (63 %); fever was the least common reaction (16 %).

CSC-nonspecific and CSC-specific immunity

Lymphocyte count and function of the first and second test were compared: the test data of all patients pre-vaccination were merged and compared with the test results obtained post-vaccination (Table 2). From the aspect of lymphocyte count, all subsets were significantly higher in the medium- and high-dose groups after vaccination; from the aspect of lymphocyte function, Th1-type cytokines were higher in the medium- and high-dose groups, while Th2-type cytokine levels were essentially unchanged.

CSC-specific immunity of the first and second test was compared: the test data of all patients pre-vaccination were merged and compared with the test results obtained post-vaccination (Fig. 4). In CSC binding by immune plasma, the proportions of positive staining were all significantly higher ($P < 0.001$, Fig. 4a) after vaccination; in CSC destruction by immune plasma, the percentage of viable cells after CDC ($88 \pm 8\%$ in test 1) was decreased in medium-dose group ($68 \pm 15\%$, $P < 0.05$) and significantly decreased in high-dose group ($46 \pm 17\%$, $P < 0.01$) (Fig. 4b). In CSC destruction by CTL, the cytotoxicity effects at three effect/target proportions were all significantly increased in the high-dose group ($P < 0.01$, Fig. 4c).

Discussion

The subject of some controversy, CSCs are considered capable of symmetric or asymmetric self-renewal,

Table 2 Comparison of number and function of lymphocyte

Test items of lymphocyte	Testing results			
	Test 1 (<i>n</i> = 90)	Test 2 (low-dose group)	Test 2 (medium-dose group)	Test 2 (high-dose group)
Number (cell/ μ L)				
Total T cell	1434 \pm 61	1512 \pm 76	1608 \pm 78*	1832 \pm 93***
CD8+ T cell	621 \pm 8	683 \pm 20	722 \pm 31*	767 \pm 13***
CD4+ T cell	735 \pm 30	801 \pm 42	821 \pm 35*	856 \pm 33**
NK cell	412 \pm 31	521 \pm 51	552 \pm 63**	622 \pm 73***
B cell	309 \pm 11	362 \pm 12	465 \pm 33**	551 \pm 41**
Function (pg/mL)				
IL-2	9.6 \pm 3.1	13.8 \pm 4.8*	17.8 \pm 3.9***	23 \pm 4.4***
TNF- β	3.8 \pm 2.2	3.7 \pm 3.8	9.8 \pm 2.5***	14 \pm 2.3***
IFN- γ	4.8 \pm 3.3	4.6 \pm 2.4	10.8 \pm 3.6***	16 \pm 3.5***
IL-4	10.2 \pm 2.1	10.2 \pm 2.7	10.1 \pm 3.4	11.2 \pm 3.1
IL-6	13.2 \pm 3.9	14.3 \pm 3.6	15.2 \pm 4.5	15.5 \pm 9**
IL-10	9.2 \pm 2.7	10.2 \pm 3.2	9.3 \pm 2.3	10.1 \pm 3.2

Every cell subset or cytokine were analyzed by Dunnett's multiple comparison test (one-way ANOVA)

NK cell natural killer cell, *IL* interleukin, *TNF* tumor necrosis factor, *IFN* interferon

* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$

resistance to standard chemotherapies or radiotherapies, less differentiated, and tumorigenic; the last is evinced by the ability of low numbers of CSCs to establish tumors in immunodeficient mice [19, 20]. As the failure of current therapies to control cancer can be attributed to their inability to eliminate CSCs, it is critical to develop strategies that eliminate these stem cell-like tumor cells. Recent data suggest that immune-based approaches may be particularly attractive prospects for targeting CSCs: one strategy is to target CSCs via monoclonal antibodies, such as CD47 [21] and CD123 [22], which have been shown to eradicate leukemia stem cells in preclinical models. Another approach involves harnessing cellular immune responses, such as anti-tumor T cells [23, 24] or anti-tumor DCs [16, 25], which have also produced good effects in animal models. Currently, commercial CSC separation and amplification kits are widely used, offering technical guarantees for the clinical application of this vaccine. This study represents the first trial of a lung CSC vaccine in clinical use and is a step forward in the exploration of cellular immune responses targeting CSCs.

Fortunately, no blood or bone marrow changes were detected in any patient; local or systemic side effects that appeared were alleviated within the day. From the perspective of efficacy, CSC-specific and CSC-nonspecific lymphocytes were both significantly increased; CSC-specific and CSC-nonspecific immunities were both continually enhanced as the number of CSCs in the vaccine increased, and severe adverse events were not observed.

At least four factors guarantee the safety and efficacy of the vaccine: (1) All patients underwent cytoreductive

surgery, radiotherapy, or cryosurgery to reduce the tumor burden, and then received the vaccination. The organ-like structural environment of tumors is very hostile toward immune cells and can result in local immune tolerance [26]; a low tumor burden provides the necessary conditions for the in vivo survival and amplification of specific lymphocytes. (2) DC activation plays a central role in lung cancer, where the level of tumor-specific lymphocytes decreases prior to tumor recurrence and increases again with immunization [27]. Our experience with animal experiments established the foundations of how and when to vaccinate [16]; although the drawing of extra blood for DC preparation is difficult, the addition of adjuvants (Mannatide injection) compensated for this drawback and produced a good immune effect. (3) Ongoing CSC cultures ensured antigen activity during vaccination and detection, which provided a further guarantee of the effects of vaccination and detection. (4) Given the individual differences of allogeneic CSCs, individualized CSC vaccines for each patient guarantee a CSC-specific response and accurate activation of the T cell repertoire.

In this study, immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement. CTLs generated from peripheral blood mononuclear cells harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro. Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity [16]. Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting




Fig. 4 Comparison of CSC-specific immunity pre- and post-vaccination. **a** Flow cytometry results of CSC-specific antibody levels in immune plasma and IgG levels. **b** CSC targeting by CSC-primed CDC; 10^5 viable CSCs were incubated with immune plasma for 1 h (control group: no immune plasma), then rabbit complement was

added and incubated for another 1 h. Viable cells were then counted under a microscope after trypan blue staining. **c** CSC targeting by CSC-primed CTLs; CSC killing was measured by a lactate dehydrogenase release assay. A higher percentage of cytotoxicity indicated more cell lysis. * $P < 0.05$; ** $P < 0.01$

CSCs and conferring antitumor immunity. Together, these proof-of-concept results provide a rationale for a new type of cancer immunotherapy based on the development of CSC vaccines that can specifically target CSCs.

Altogether, this study first demonstrated the safety and efficacy of the lung CSC vaccine in a clinical trial, but the vaccine requires further refining. At the cellular level, CSCs might modulate the immune responses via several mechanisms. For example, CSCs may selectively not express tumor-associated antigens associated with differentiation and may therefore be resistant to immune-mediated rejection or evade host immunosurveillance through the absence or downregulation of major histocompatibility complex class I molecules [28]. Therefore, the mechanism by which the lung CSC vaccine strengthens the specific and nonspecific responses requires further investigation. From the viewpoint of a long-term curative effect, the benefit of this vaccine on progression-free survival and overall survival also requires further research.

Acknowledgments We would like to thank the native English-speaking scientists of Elixigen Company for editing our manuscript. The project was funded by the Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (Program No. is 2008DP173344).

Conflict of interest None.

References

1. Jemal A, et al. Global cancer statistics. *CA Cancer J Clin*. 2011;61:69–90.
2. Choudhury A, et al. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. *Clin Lung Cancer*. 2008;9(Suppl 1):S37–44.
3. Grilli R, et al. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? *J Clin Oncol*. 1993;11: 1866–72.
4. Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*. 2002;346: 92–8.

5. Sharma A, et al. How I do it: radiofrequency ablation and cryoablation of lung tumors. *J Thorac Imaging*. 2011;26:162–74.
6. Maiwand MO, et al. The application of cryosurgery in the treatment of lung cancer. *Cryobiology*. 2004;48:55–61.
7. Gerard C, et al. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. *Mol Oncol*. 2009;3:409–24.
8. Shi SB, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. *Tumori*. 2012;98:314–9.
9. Zhao M, et al. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. *Exp Ther Med*. 2014;7:1403–7.
10. Shi SB, et al. Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. *J Immunother*. 2014;37:250–5.
11. Alamgeer M, et al. Cancer stem cells in lung cancer: evidence and controversies. *Respirology*. 2013;18:757–64.
12. O'Flaherty JD, et al. The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. *J Thorac Oncol*. 2012;7:1880–90.
13. Lundin A, et al. Lung cancer stem cells: progress and prospects. *Cancer Lett*. 2013;338:89–93.
14. Qu H, et al. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. *Int J Clin Exp Pathol*. 2013;6:2644–50.
15. Chen Y, et al. The utilization and limitation of CD133 epitopes in lung cancer stem cells research. *Zhongguo Fei Ai Za Zhi*. 2011;14:825–9.
16. Ning N, et al. Cancer stem cell vaccination confers significant antitumor immunity. *Cancer Res*. 2012;72:1853–64.
17. Yuanying Y, et al. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. *Cryobiology*. 2013;67:235–40.
18. Goldberg SN, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. *J Vasc Interv Radiol*. 2005;16:765–78.
19. Dick JE. Stem cell concepts renew cancer research. *Blood*. 2008;112:4793–807.
20. Visvader JE. Cells of origin in cancer. *Nature*. 2011;469:314–22.
21. Majeti R, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. *Cell*. 2009;138:286–99.
22. Jin L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemia stem cells. *Cell Stem Cell*. 2009;5:31–42.
23. Schatton T, et al. Antitumor immunity and cancer stem cells. *Ann N Y Acad Sci*. 2009;1176:154–69.
24. Sato N, et al. Molecular pathological approaches to human tumor immunology. *Pathol Int*. 2009;59:205–17.
25. Xu Q, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. *Stem Cells*. 2009;27:1734–40.
26. Plate J. Clinical trials of vaccines for immunotherapy in pancreatic cancer. *Expert Rev Vaccines*. 2011;10:825–36.
27. Wright SE. Immunotherapy of breast cancer. *Expert Opin Biol Ther*. 2012;12:479–90.
28. Aptsiauri N, et al. Role of altered expression of HLA class I molecules in cancer progression. *Adv Exp Med Biol*. 2007;601:123–31.